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Introduction
Acinetobacter baumannii is a non-motile, aerobic, Gram-
negative opportunistic pathogen often causing serious, life-
threatening infections found most frequently in healthcare-
associated infections (HAI), including ventilator-associated 
pneumonia (VAP) [1]. Effective treatments for the management 
of invasive A. baumannii infections are significantly limited 
due to high rates of resistance to fluoroquinolones, tigecycline, 
aminoglycosides, and β-lactams including carbapenems [2]. 
This  is  particularly  notable  in  isolates  associated  with 
HAI (up to 63% in one report) [3]. For these reasons, A. 
baumannii has been identified together with other notable 
nosocomial multi-drug resistant (MDR) organisms as an 
ESKAPE pathogen (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pnemoniae, Acinetobacter baumannii, 
Pseduomonas aeruginosa, and Enterobacter species) [4]. 
Due to the continued global rise in A. baumannii resistance, 
in 2013 the Centers for Disease Control and Prevention (CDC) 
declared MDR A. baumannii a serious threat [3]. Carbapenem 
resistance in A. baumannii is independently associated with 
increased hospital mortality and prolonged ICU and hospital 
stays [6,7]. In 2017, the World Health Organization (WHO) 
placed carbapenem-resistant A. baumannii (CRAB) on its 
global priority list as a critical threat to promote and encourage 
the research and development of new antibiotics [5,8].
Currently, there are a limited number of effective therapies 
targeting this highly resistant pathogen [9]. The  polymyxins, 
minocycline,  tigecycline,  amikacin,  and  sulbactam-
containing agents are potential antimicrobial treatment 
options, yet significant limitations exist for each agent. 
These include increasing rates of resistance, inadequate 
in vitro susceptibility testing methods, suboptimal tissue 
concentrations, and toxicity profiles. Emerging treatment 
options include the combination of “older” agents, new 
antibiotics, and novel (non-antibiotic) therapies. It is 
the objective of this review to describe the mechanisms, 
epidemiology, and the current and developing management 
strategies of invasive infections due to MDR A.baumannii.
Mechanisms of Antimicrobial 
Resistance
While definitions vary between sources, the term MDR most 
often refers to in vitro resistance to 3 or more antimicrobial 
classes, while extensively drug-resistant (XDR) is generally 
used to describe resistance that excludes most standard 
antimicrobial classes [10]. While MDR isolates may be 
susceptible to a carbapenem in vitro, XDR A. baumannii is most 
often carbapenem-resistant. For A. baumannii, pan-resistance 
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(PDR) describe isolates with in vitro resistance to all β-lactams 
(including carbapenems), aminoglycosides, fluoroquinolones, 
and polymyxins [10].
While not the most common of the ESKAPE pathogens, A. 
baumannii is considered one of the most serious threats to 
healthcare due to its extraordinary ability to quickly adapt 
to selective environmental pressures (notably antibiotics) 
[4,11,12]. Mechanisms of drug resistance are diverse and 
include β-lactamase production, multidrug efflux pumps, 
aminoglycoside-modifying enzymes, permeability defects, and 
alteration in target binding sites [13,14]. These mechanisms 
often work in tandem to convey resistance to multiple antibiotic 
classes. Resistance may be a result of both vertical transfer 
and its natural ability to integrate exogenous DNA into its own 
genome [11].
Production of β-lactamases is generally considered to be 
the most prevalent mechanism of antibiotic resistance in A. 
baumannii. Each of the Ambler classes of β-lactamases (Class 
A-D) have been isolated from A. baumannii, conferring 
resistance to many commonly used β-lactam antibiotics [11]. In 
addition to the intrinsic Class C β-lactamases, other serine-
dependent β-lactamases include Class A β-lactamases (TEM, 
SHV, CTX-M, KPC, and others) that hydrolyze penicillin and 
cephalosporins and Class D β-lactamases, oxacillinases (OXA). 
Class D β-lactamases are the most prominent β-lactamase 
conferring resistance to carbapenems via enzymatic degradation 
with MDR isolates often containing more than one oxacillinase. 
Class B β-lactamases, or metallo-β-lactamases (MBL), are 
the broadest spectrum β-lactamase that hydrolyze almost all 
β-lactams, including carbapenems. A number of MBL enzymes 
have been recognized in A. baumannii including IMP, VIM, and 
NDM [13,15].
In addition to β-lactamase production, other well-described 
mechanisms contributing to MDR isolates include efflux 
pumps, decreased permeability of the cell wall, and alterations 
in target sites. Two efflux pumps, tet(A) and tet(B), are 
tetracycline specific efflux pumps that confer resistance to 
most tetracyclines, with the exception of tigecycline [16]. 
Tet(A) confers resistance to tetracycline, while tet(B) is highly 
suggestive for minocycline resistance [11,17,18]. Multidrug 
efflux pumps, such as AdeFGH and AdeABC, increase resistance 
to many antibiotics, including carbapenems, tetracyclines, 
and even tigecycline [11,15]. Interestingly, subinhibitory 
concentrations of antibiotics due to low-dose treatment can 
induce upregulation of the AdeFGH efflux pump, thereby 
increasing biofilm formation [19]. The AdeABC efflux pump is 
the most well-described multidrug efflux pump in A. baumannii 
and effects β-lactams, aminoglycosides, tetracyclines, 
fluoroquinolones, and others [11]. The AdeABC efflux pump 
can also be upregulated when exposed to subinhibitory 
concentrations. This mechanism may be most notable when 
exposing A. baumannii to subinhibitory concentrations of 
tigecycline, such as for treatment of bacteremia, as increased 
minimum inhibitory concentrations (MICs) have been 
found in vitro and likely contribute to poor clinical outcomes 
[20]. A reduction in porin channels affecting membrane 
permeability of many antibiotics have also been reported, while 
a downregulation or alteration in lipopolysaccharides found 
on the outer membrane of A. baumannii increases resistance 
to colistin [21]. Finally, overexpression or alteration of target 
sites via penicillin-binding protein (PBP) result  in decreased 
susceptibility of  carbapenems, while the presence of GyrA 
or aminoglycoside-modifying enzymes are key contributors to 
quinolone and aminoglycoside resistance, respectively [15].
Epidemology of MDR and XDR A. 
baumannii Infections
With the capabilities of forming biofilm and its propensity to 
survive harsh, dry conditions, A. baumannii is a significant 
hospital-acquired pathogen, particularly found in the 
intensive care units (ICU) [22]. Risk factors for Acinetobacter 
spp acquisition include receipt of broad-spectrum antibiotics 
(specifically later generation cephalosporins), receipt and 
duration of mechanical ventilation, ICU admission and duration 
of stay, invasive procedures or devices, total parenteral nutrition, 
and exposure to contaminated sources [1]. While most notable 
for causing respiratory tract infections (including VAP), it has 
also been reported to cause bloodstream infections (BSI), wound 
or acute bacterial skin and skin structure infections (ABSSSI), 
complicated urinary tract infections (cUTI), complicated intra-
abdominal infections (cIAI), and meningitis [1]. A. baumannii 
has the propensity for biofilm formation, making it particularly 
difficult to eradicate in certain conditions (notably on blood and 
urinary catheters and endotracheal tubes) [23]. According to 
the National Healthcare Safety Network (NHSN), A. baumannii 
is the fifth most common VAP pathogen, accounting for 6.1% to 
7.5% of all cases [24,25]. Despite only 2% of HAIs are caused 
by Acinetobacter spp., crude mortality in patients with A. 
baumannii infections can be as high as 75% [3,26].
Antimicrobial resistance in A. baumannii has demonstrated 
notable increases in the last several years. For example, the 
Meropenem Yearly Susceptibility Test Information Collection 
Program demonstrated a 61% increase in meropenem resistance 
over a 10-year period (1999-2008). Tobramycin maintained 
the highest susceptibility rate over this period (59.1%) followed 
by meropenem (45.7%), levofloxacin (33.9%) and ceftazidime 
(31.5%) [2]. In a more recent global pooled prevalence study 
assessing resistance in A. baumannii infections from countries 
participating in the Organization for Economic Cooperation and 
Development, a 55.7% meropenem resistance rate was reported 
from 2006-2016. Meropenem resistance increased dramatically 
from 25.7% in the years 2000 to 2005 compared to 55.6% from 
2006 to 2010 and increased further to 70.1% from 2011 to 
2016. Amikacin resistance increased from 38.2% to 43.6% to 
66.6% over the same period, respectively [27].
Limitations of Established Monotherapy 
Treatments for MDR A. baumannii
Polymyxins
Discovered over 70 years ago, use of the polymyxins (polymyxin 
B and colistin) have reemerged due to the rise in MDR Gram-
negative pathogens, including (but not limited to) CRAB. Use of 
polymyxins is generally limited by a narrow therapeutic window, 
with the most significant  (often  treatment-limiting)  adverse 
effects  of  nephrotoxicity  and  neurotoxicity (occurring in 
6% to 55% and 7% to 27% of patients, respectively) [28,29]. 
Polymyxins are further restricted from widespread use in 
invasive infections due to lack of optimal exposure targets in 
critically ill patients and lack of reliable in vitro colistin testing 
[30].
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Since colistin is administered as the inactive prodrug 
formulation, colistin methanesulfonate (CMS), some 
hypothesize that the delayed conversion to the active 
form may result in reduced bacterial killing and promote 
the development of treatment-emergent resistance or in 
subsequent A. baumannii isolates [31-33]. When colistin MICs 
to A. baumannii approach  the  susceptible breakpoint (< 2 μg/
mL, see Table 2), attaining adequate serum concentrations 
in subjects with normal renal function is reported in only 30-
40% of patients receiving loading doses and at the maximum 
recommended maintenance dose  (capped  due  to  increased 
toxicity risks) [30,34]. Likewise, at the highest recommended 
doses, polymyxin B is not consistently effective at achieving 
optimal respiratory tract concentrations [30]. Furthermore, 
rates of colistin resistance in respiratory isolates are increasing 
[12,35]. The most concerning report of colistin resistance is 
from a collection of VAP isolates from Europe. These isolates 
demonstrated a 47.7% resistance rate with an MIC50/90 
of 2 μg/mL and 256 μg/mL, respectively [12]. Previous 
treatment with colistin is regarded as a significant risk factor 
for the development of colistin heteroresistance, with colistin 
resistance being associated with poor clinical outcomes [36-38]. 
This is most evident in a report of 19 patients infected with a 
colistin-susceptible isolate and treated with intravenous CMS, 
inhaled CMS, or both [37]. Colistin resistance was isolated in 
all 19 patients after a median interval of 20 days. Of note, the 
authors do not comment on the dosing of CMS. Retrospective 
evaluations of colistin monotherapy versus a monotherapy 
comparator agent (ampicillin/sulbactam) in the treatment 
of mixed CRAB infections demonstrated increased 30-day 
mortality and mortality during therapy in the colistin cohorts 
[39,40]. In a prospective evaluation of 28 MDR A. baumannii 
VAP patients treated with colistin or imipenem-cilastatin, 
clinical efficacy was similar among cohorts (60.0% vs 61.5%) 
[41]. Efficacy data for the use of monotherapy polymyxins for 
MDR A. baumannii remain scarce with contrasting outcomes. 
Irrespective of the preceding limitations, polymyxins remain 
as a primary treatment option for MDR A. baumannii with the 
majority of clinical data surrounding polymyxins as combination 
therapy.
Minocycline 
Minocycline is yet another agent with a recent resurgence due to 
carbapenem- resistant Gram-negative infections, most notably 
CRAB. Following a brief hiatus, intravenous minocycline 
was re-introduced to the market in 2009 and is accompanied 
with an FDA-approved indication for infections caused by 
Acinetobacter spp. In vitro data suggests minocycline may 
play a role in the treatment of infections involving prosthetic 
material. In one study, minocycline prevented biofilm formation 
in 96% of biofilm-forming A. baumannii isolates [42]. In vitro 
susceptibility of A. baumannii to minocycline ranges from 70.3% 
to 79.1% in highly carbapenem-resistant isolates (meropenem 
susceptibilities ranging from 8.7% to 36.4%) [16,43,44]. In 
contrast, only 37.8% of 200 carbapenem-resistant isolates 
were minocycline susceptible in one report [45]. The majority 
of minocycline resistance (71.1%) in  A.  baumannii was due to 
the presence of the tet(B) clinical strains, whereas when this 
efflux pump was absent, only 6.7% of isolates were resistant 
[18]. Clinical success rates in CRAB VAP patients treated with 
minocycline are high (> 80%), yet clinical data are extremely 
limited and generally associated with combination therapy [46].
Tigecycline 
Tigecycline, a glycylcycline, is a semisynthetic derivative 
of minocycline that is able to overcome most tetracycline 
resistance mechanisms. Pharmacokinetic limitations, risk of 
treatment-emergent failure, and higher mortality (compared 
to imipenem-cilastatin) in HAP/VAP treated patients limit 
its widespread use [11,47]. Currently, no Clinical Laboratory 
Standards Institute (CLSI)-approved breakpoints for tigecycline 
against A. baumannii exist, and (as expected) variability 
in  testing  methods  have  produced  inconsistent  in  vitro 
susceptibility  results [48,49]. Although worldwide surveillance 
studies show that the MIC90 against MDR A. baumannii isolates 
has remained at 2 μg/mL, treatment-emergent resistance has 
occurred in various case reports at standard dosing [44,50] . 
This is thought to be a result of suboptimal concentrations of 
tigecycline (notably in the treatment of bacteremia) combined 
with overexpression of efflux pumps [20,32,50]. Clinical data 
concerning tigecycline treatment, often in combination, are 
not promising as higher rates of in-hospital mortality were 
observed [51]. Due to these limitations, tigecycline’s current 
role is generally restricted to the treatment of colistin-resistant 
isolates or as part of combination therapy to prevent the 
emergence of colistin resistance or heteroresistance.
Amikacin 
The emergence of resistance to all aminoglycosides is due 
to the production of aminoglycoside-modifying enzymes or 
efflux pumps mechanisms in MDR A. baumannii strains [11]. 
Amikacin is an aminoglycoside used in the treatment of A. 
baumannii infections since it often retains in vitro susceptibility 
to CRAB isolates. However, resistance rates to amikacin have 
been on the rise [27]. In one report, less than 20% of CRAB 
isolates maintained susceptibility to amikacin [52]. Treatment-
emergent resistance to amikacin has also been shown to 
develop [53]. Clinical studies evaluating amikacin monotherapy 
against A. baumannii infections are lacking.
Sulbactam-containing regimens
Sulbactam, a class A β-lactamase inhibitor, has intrinsic in 
vitro activity against A. baumannii and exhibits high-affinity 
for penicillin-binding proteins (notably types 1a and 2) [54]. 
However, resistance to sulbactam-containing combinations 
(such as ampicillin or cefoperazone) has dramatically increased 
with MICs often > 16 μg/mL. One study reports ampicillin-
sulbactam resistance rates at 72.3% in the years 2011-
2016 [27]. In  another report, rates of ampicillin/sulbactam 
susceptibility to carbapenem-susceptible strains was 94.1%, yet 
when tested against the carbapenem-resistant phenotype, only 
19.4% remained susceptible [45].
For these reasons, the majority of sulbactam-containing studies 
in the treatment of A. baumannii have been in combination with 
other therapies. In a pooled analysis of 13 studies, including one 
prospective study, sulbactam-containing combination regimens 
were similar in terms of clinical response, bacteriological 
response and in-hospital mortality compared to the control 
group. When analyzing for dose, the high-dose regimen 
(sulbactam > 9 g/day) was found to be more effective and was 
well tolerated without serious adverse effects [55]. High-dose 
sulbactam- containing regimens may be a suitable treatment 
option for CRAB at an MIC ≤ 4 μg/mL to preserve other 
therapies and better safety profile.
Combination Therapies
The vast majority of data surrounding combination therapies 
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Table 1. In vitro activity of select therapies against carbapenem-resistant A. baumannii isolates
Novel Therapy Number of CRAB 
isolates
MIC50 
(μg/mL)
MIC90 
(μg/mL)
MIC Range
(μg/mL)
Reference
Eravacycline 286 0.5 1 < 0.06 to > 64 [82]
707 1 2 0.06 to 8 [158]
52 0.5 2 < 0.016 to 4 [159]
193 1 2 0.12 to 8 [119]
Cefiderocol 595 (EU) 0.12 1 0.004 to 64 [101]
173 (NA) 0.25 1 < 0.002 to 8 [101]
562 0.5 2 < 0.002 to > 256 [102]
100 0.5 8 0.06 to > 64 [103]
768 0.12 1 < 0.002 to 64 [104]
107 0.06 0.5 < 0.03 to 2 [105]
44 0.12 1 0.012 to 4 [160]
ETX2514SUL 731 1 4 < 0.06 to 32 [54]
72 1 2 N/A [109]
TP-6076 121 0.03 0.06 < 0.002 to 0.12 [117]
326 0.06 0.125 0.008 to 0.5 [119]
41 0.008 0.063 0.002 to 0.25 [108]
EU: Europe; NA: North America; MIC50: minimum inhibitory concentration at which 50% of isolates are inhibited; MIC90: minimum inhibitory concentration 
at which 90% of isolates are inhibited; CRAB: carbapenem-resistant Acinetobacter baumannii
Table 2. In vitro susceptibility testing of select therapies for A. baumannii isolates [34].
Antimicrobial Agent Interpretive Categories and
MIC breakpoints (μg/mL)
Comments
S I R
Colistin < 2 > 4 •	 BMD is only approved MIC testing method; disk diffusion 
and gradient diffusion methods should not be performed
•	 Predicts MIC to polymyxin B
Minocycline < 4 8 > 16 •	 A. baumannii that are susceptible to tetracycline predicts 
susceptibility to minocycline. If intermediate/resistant to 
tetracycline, susceptibility to minocycline cannot be assured
Tigecycline - - -
Amikacin < 16 32 > 64
Ampicillin/sulbactam < 8/4 16/8 > 32/16
Meropenem < 2 4 > 8 •	 Breakpoints are based on a dosage regimen of 1 g adminis-
tered every 8 h or 500 mg administered every 6 h
Eravacycline - - -
Omadacycline - - -
Cefiderocol < 4 8 > 16 •	 Breakpoints based on a dosage regimen of2 g every 8 h 
administered over 3 h
•	 Testing cefiderocol required iron-depleted cation-adjusted 
Mueller-Hinton broth (CAMHB). Chelation is used for iron 
depletion, which removes other cations (calcium, magne-
sium, and zinc). Following this process, cations are added 
back to concentrations of calcium 20-25 mg/L, magnesium 
10-12.5 mg/L, and zinc 0.5-1.0 mg/L
MIC: minimum inhibitory concentration; S: susceptible; I: intermediate; R: resistant; BMD: broth microdilution
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of A. baumannii treatment are in patients with pneumonia 
or mixed infections. Polymyxin-based therapies were most 
commonly studied (> 50%), while tigecycline-based therapies 
were the next most frequent (25%) [34].
Several in vitro studies have shown synergistic effects of colistin 
in combination with sulbactam, tigecycline, carbapenems, 
glycopeptides, and others [56]. In addition, combination 
regimens may improve microbiological cure rates (when 
compared to monotherapy), yet has rarely translated to 
improved clinical outcomes, specifically reductions in mortality 
[57]. To date, five prospective trials have evaluated colistin-
based regimens combined with rifampin, fosfomycin (twice), 
ampicillin- sulbactam, and meropenem for MDR Gram-
negative bacteria, primarily A. baumannii [58-62]. When these 
data are combined, colistin combination therapy showed 
no difference for in-hospital morality and clinical response. 
Only the combination with ampicillin/sulbactam (n=39) was 
associated with a favorable clinical response compared to 
colistin monotherapy, whereas the remaining studies showed 
no difference for in-hospital mortality and clinical response 
[60,63]. While polymyxin-based therapies appear to offer 
no additional benefit over monotherapy groups, significant 
limitations to the available data remain. These include high 
mortality or treatment failure regardless of treatment, 
documentation of time to appropriate therapy, use of colistin 
rather than polymyxin B in invasive infections, and suboptimal 
reporting of MICs, dosing regimens, and use of concomitant 
antibiotics [30].
The majority of data for tigecycline-based combination therapies 
are limited to retrospective data in pneumonia treated patients, 
mainly VAP, and clinical outcomes are not promising. In two 
retrospective studies evaluating tigecycline monotherapy (100 
mg IV loading dose, then 50 mg IV  q12h)  versus  tigecycline-
based  combination  therapy  (multiple  agents),  there  was 
no difference in clinical success, mortality, or microbiological 
outcomes [64,65]. Similarly, when evaluating tigecycline-based 
combination therapy versus non-tigecycline-based combination 
therapy, clinical cure and mortality outcomes were similar 
[66-69], while microbiological eradication with tigecycline-
based therapy was significantly lower in one trial [67]. In a 
more recent evaluation of 238 adult ICU patients with CRAB 
pneumonia, those treated with tigecycline-based combination 
therapies had higher ICU mortality than non-tigecycline 
therapy (adjusted odds ratio 2.30, 95% confidence interval 
1.19-4.46) [70]. When the data are combined, treatment with 
tigecycline for MDR A. baumannii is associated with higher 
in-hospital mortality and trended towards a longer hospital 
stay; however, monotherapy versus combination therapies 
did not show the same difference [51]. While the data for 
tigecycline-combination therapies has obvious limitations, 
there seems to be no additional benefit of combination therapy 
with tigecycline. 
Data regarding use of minocycline combination are also 
sparse. A retrospective review of 36 VAP patients with CRAB 
isolates and treated with minocycline/doxycycline found a 
clinical response rate of 81.8% (n=11) for the monotherapy group 
and 80.0% (n=25) in those receiving minocycline-combination 
therapy [46]. Another retrospective review demonstrated 
a  clinical success rate of 40/55 (73%) in patients treated 
with minocycline for MDR A. baumannii infection of various 
types. Of those 55 patients, only three received treatment with 
minocycline monotherapy while 52 received combination with 
another active agent [71]. While doses utilized in these studies 
ranged from 200-400 mg daily, one study suggests utilizing 
high dose minocycline (e.g. 700 mg daily) or as combination 
therapy to prevent rapid emergence of  resistance [5]. However, 
the safety and tolerability of such regimens has not been 
established.
Pharmacokinetic / Pharmacodynamic 
(PK/PD)-Based Dosing
With the rising of resistance rates of A. baumannii and the 
lack of new antimicrobials to the marketplace in recent years, 
clinicians have pursued optimizing the dosing of existing agents 
based on their PK/PD properties. This includes utilizing higher 
doses, shortening the dosing interval and prolonging infusion 
times. Each of these principles may be applied to β-lactams 
(eg, carbapenems, ampicillin/sulbactam) as they demonstrate 
a time-dependent antibacterial activity with maximal 
bactericidal effects occurring at serum concentrations 
approximately four times the MIC of the pathogen for at least 
40% of the dosing interval [72]. Additionally, greater clinical 
cure and bacteriological eradication is achieved if the free drug 
concentration remains above the MIC of the pathogen for 100% 
of the dosing interval in critically ill patients [73].
While high-quality efficacy data are limited with this 
approach, β-lactam agents are generally well tolerated without 
an increased risk of toxicity when intermittent infusions were 
compared to prolonged infusion strategies. In the largest 
of these randomized control trials (all pathogens n=214, 
Acinetobacter spp. n=20), continuous infusion meropenem 
had a similar clinical cure rate when  compared  to  intermittent 
dosing [74]. Higher microbiological success  rates, shorter ICU 
lengths of stay, and shorter durations of meropenem therapy 
were observed with no difference in safety outcomes. In a 
meta-analysis comparing prolonged infusions to intermittent 
bolus doses of meropenem, the prolonged infusion cohort 
had higher rates of clinical success (OR 2.10, 95% CI 1.31-
3.38) and lower mortality (RR 0.66, 95% CI, 0.50-0.88) [75]. 
In the single study evaluating 30 HAP patients with MDR A. 
baumannii isolates, no difference in clinical efficacy or relapse 
rates were observed among cohorts [76]. Of note, doripenem 
is the lone carbapenem that should not utilize prolonged 
infusions, as higher mortality rates were seen among patients 
with microbiologically confirmed late-onset VAP [77].
To overcome suboptimal tigecycline concentrations, a phase 
II study and a retrospective analysis demonstrated higher 
tigecycline doses (100 mg IV every 12 hr) in VAP-treated 
patients were associated with improved clinical cure rates 
compared to standard doses without increases in adverse 
events [78,79]. While higher doses may be warranted in severe 
infections (eg, pneumonia), clinical data are limited due to early 
termination of the phase II study due to poor recruitment.
Newly Approved Therapies
Eravacycline 
Eravacycline (Xerava™) is a novel, fully synthetic fluorocycline 
antibiotic approved by the FDA in August 2018. Similar to 
other tetracycline derivatives, it inhibits bacterial protein 
synthesis by binding to the 30S ribosomal subunit [80]. 
Eravacycline is structurally similar to tigecycline, except it has 
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two modifications to the D-ring core at C-7 and C-9 [80]. These 
modifications enhance its antibacterial spectrum of activity and 
its stability against tetracycline- specific resistance mechanisms 
(e.g. efflux pumps and ribosomal protection proteins) [81].
Eravacycline demonstrates a broad spectrum of activity in 
vitro against aerobic and anaerobic Gram-positive and Gram-
negative pathogens, including MDR A. baumannii [80,82-
84]. The MIC50/90 were 0.06/0.5 μg/mL and 0.5/1 μg/
mL(respectively) against A. baumannii isolates from patients 
in 13 Canadian hospitals and 11 hospitals in New York 
[81,84]. Another study reported MIC50/90 values against 
CRAB isolates of 0.5 μg/mL and 1 μg/mL, respectively (Table 
1) [82]. In two in vitro studies, 89% and 96% of CRAB isolates 
had eravacycline MICs of ≤ 1 μg/mL [82,83]. When compared 
to tigecycline, eravacycline has been shown to be two- to four-
fold more potent than tigecycline against A. baumannii isolates, 
including carbapenem-resistant isolates [81-84].
The efficacy of eravacycline has been evaluated in several Phase 
II and III studies for the management of cIAI and cUTIs [85-88]. 
Despite these numerous studies, efficacy relating to infections 
caused by A. baumannii is limited. In a pooled analysis of the 
IGNITE 1 and 4 studies, the clinical and microbiological response 
rates were 100% for patients with A. baumannii, including 
MDR isolates [89]. Of note, IGNITE 1 only had 8 patients and 
IGNITE 4 had 5 patients with A. baumannii infections [85,90]. 
In contrast, the efficacy of eravacycline in cUTIs has not been as 
promising [88,91]. Eravacycline is eliminated predominately in 
the feces (with low urinary excretion), suggesting eravacycline 
may not be an effective treatment option for UTIs caused by 
MDR A. baumannii.
Eravacycline has been well-tolerated in clinical studies and 
most adverse events have been similar to comparator agents 
with a few exceptions. Notably, the reported incidences of 
infusion site reactions, nausea, and vomiting have been higher 
compared to carbapenems [80]. Despite higher incidences of 
nausea and vomiting compared to carbapenems, they are still 
significantly lower than those reported with tigecycline (6.5% 
vs 26% and 3.7% and 18%, respectively) [44,80]. One potential 
disadvantage of eravacycline compared to other therapies 
for MDR A. baumannii is the concern for drug interactions. 
Eravacycline is a substrate for the CYP450 enzyme system, 
specifically CYP3A. When administered concomitantly with a 
strong CYP3A inducer (e.g. rifampin), the dose of eravacycline 
should be increased to 1.5 mg/kg IV every 12 hours. There 
are no formal recommendations regarding eravacycline and 
strong CYP3A inhibitors at this time. Additionally, eravacycline 
has the potential to increase the effects of warfarin, thus dose 
adjustments may be warranted [80].
Omadacycline 
Omadacycline (NUZYRA™) is a semisynthetic derivative of 
minocycline and is a novel aminomethylcycline antibiotic. Much 
like eravacycline, omadacycline has the ability to remain active 
in the presence of tetracycline efflux and ribosomal protection 
genes resulting in a broad spectrum of activity [92].
In vitro omadacycline data against a collection of 2101 
worldwide clinical isolates of A. baumannii demonstrated an 
MIC50/90 of 2 μg/mL and 4 μg/mL, respectively, with 91.5% of 
isolates inhibited at MIC values < 4 μg/mL [92]. In a collection 
of 441 A. baumannii isolates from 2016, omadacycline 
MIC50/90 values were slightly higher at 4 μg/mL and 8 μg/mL, 
respectively, while 71.2% of isolates were inhibited at an MIC 
of < 4 μg/mL. Additionally, in the 293 tetracycline resistance 
strains, the MIC50/90 values were unchanged, although only 
57.3% of strains were inhibited at 4 μg/mL [93].
Omadacycline was granted FDA approval in October 2018 for 
the treatment of community-acquired  bacterial  pneumonia 
(CABP)  and  ABSSSI [73]. In  two  randomized  controlled 
trials, OPTIC and OASIS-1, treatment with omadacycline 
was noninferior for early clinical response when compared to 
moxifloxacin and linezolid, respectively [94,95]. However, 
both trials failed to include MDR Gram-negative pathogens, 
including A. baumannii. While studies are nearing 
completion for cystitis and pyelonephritis, it is unlikely that 
these will provide any useful data to its clinical utility in the 
treatment of A. baumannii.
Agents Undergoing Phase I-III Clinical 
Trials in the US
Cefiderocol 
Cefiderocol (previously S-649266) is a parenteral siderophore 
cephalosporin currently in phase III clinical trials for the 
treatment of nosocomial pneumonia and other severe infections 
caused by Gram-negative pathogens [96,97]. Cefiderocol has 
a unique catechol moiety at the C-3 position contributing 
to its mechanism of action, ability to chelate with ferric iron, 
and ultimately  bacterial  cell  entry.  Termed  a  “Trojan 
horse”  antibiotic  through  a  strategy  of exploiting the iron 
transport mechanism of bacteria, the siderophore-drug 
complex selectively interacts with the siderophore receptors 
on the bacterial cell surface to be actively transported across 
the  outer  membrane.  Due  to  this  mechanism,  this  novel 
antimicrobial  is  able  to circumvent permeability-mediated 
drug resistance [98,99]. The halogenated catechol group 
along with the quaternary amine at the C-3 position produces 
increased in vitro activity when certain MBLs, KPC and OXA 
producing strains are present [100].
Cefiderocol demonstrates potent in vitro activity in isolates 
tested against a broad range of ESBL-producing Gram-
negative organisms, including MDR and XDR P. aeruginosa 
and A. baumannii (susceptible breakpoint of 4 μg/mL, see 
Table 2), with negligible activity against Gram-positive aerobic 
and anaerobic bacteria [98]. When tested against 1148 A. 
baumannii isolates from North America and Europe, the MIC90 
value for cefiderocol was 1 μg/mL. When evaluated against 
CRAB, cefiderocol retained an MIC90 of 1 μg/mL and 96.9% 
(744/768) of meropenem-nonsusceptible isolates had MICs of 
< 4 μg/mL [101]. Other studies confirmed this potent activity 
against CRAB isolates ranging from 88% to 96.9% with MICs 
of < 4 μg/mL [102-104]. With regard to colistin-nonsusceptible 
strains of A. baumannii (n=121), cefiderocol’s MIC range was  < 
0.002 to 8 μg/mL with an MIC90  of 2 μg/mL [101].
 In another 
study comparing colistin-resistant strains versus  colistin  non-
resistant  strains,  the  MIC  range  of  cefiderocol  did  not  differ 
[105]. When evaluating specific carbapenemase enzymes, there 
does not appear to be a correlation of carbapenemase production 
and cefiderocol resistance [104]. Of note, the mechanisms 
conferring elevated MICs are currently being evaluated [104].
Cefiderocol has been well tolerated in phase I and II studies with 
its safety profile being similar to that of other cephalosporins 
[106,107]. Most adverse events have been gastrointestinal 
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related (diarrhea, constipation, nausea, vomiting) while 
occurring less frequently than the comparator agent (12% 
vs 18%, respectively) [107]. Cefiderocol is a β-lactam with a 
chemical structure most closely related to cefepime. Allergic 
reactions are possible, however, only one patient discontinued 
treatment due to urticaria during the infusion. This adverse 
event was deemed not to be an antibody-mediated reaction 
[106].
To date, the efficacy of cefiderocol has been evaluated in 
one completed Phase II trial. This study included 452 patients 
for the treatment of cUTI at risk for MDR Gram-negative 
uropathogens, primarily E. coli and K. pneumoniae (no A. 
baumannii isolates noted), compared to high-dose imipenem-
cilastatin. Cefiderocol met the noninferiority primary endpoint 
of the composite of clinical and microbiological outcomes at the 
test-of-cure (73% vs 55%, p=0.0004) and achieved superiority 
in the post-hoc analysis [107].
Two phase III clinical trials focusing on the treatment of invasive 
MDR pathogens are currently enrolling patients [96,97]. The 
CREDIBLE-CR trial (NCT02714595) is estimated to enroll 
150 patients to compare cefiderocol to best available therapy 
(a polymyxin-based or non-polymyxin based regimen) for the 
treatment of severe infections (BSI, HAP/VAP, cUTI, sepsis) 
caused by CR Gram-negative pathogens [96]. The APEKS-NP 
trial (NCT03032380), is estimated to enroll approximately 300 
patients to compare 14-day all-cause mortality with cefiderocol 
versus meropenem (both in association with linezolid) in adults 
for the treatment of nosocomial pneumonia caused by Gram-
negative pathogens [97].
ETX2514 + sulbactam (ETX2514SUL) 
ETX2514, a novel diazabicyclooctane β-lactamase inhibitor, 
also has intrinsic activity to Enterobacteriaceae and also 
has the ability to fully restore sulbactam’s activity against 
A. baumannii while protecting against all serine-dependent 
β- lactamases (Class A, C, and D) [108]. In a globally diverse 
collection of A. baumannii isolates (n=1131), the in vitro activity 
of ETX2514SUL was 16-fold more active than sulbactam alone 
(MIC90 4 μg/mL vs 64 μg/mL, respectively) [54]. Additionally, 
ETX2514SUL retained the same activity when subsets of 
meropenem-resistant (Table 1), colistin-resistant, and MDR 
isolates were evaluated, while there was reduced  activity 
against one isolate containing an  MBL [54]. Similarly, a 
study of 72 A. baumannii isolates with the majority being 
MDR isolates, had an MIC90 of 2 μg/mL [109]. Spontaneous 
resistance has not been observed and the use of this agent 
has not resulted in the generation of resistant β-lactamases to 
ETX2514SUL [110].
One phase II study has been completed with positive results 
[111]. This phase II double-blind, placebo-controlled trial of 
80 patients compared ETX2514SUL (1g/1g q6h for 7 days) 
plus imipenem-cilastatin to imipenem-cilastatin plus placebo 
in adult patients with cUTI including acute pyelonephritis. 
Outcomes were similar between the two groups. In an 
exploratory analysis, eight patients had imipenem-non-
susceptible pathogen resulting in microbiological eradication 
in 3/3 (100%) in the ETX2514SUL plus imipenem-cilastatin 
cohort vs 3/5 (60%) patients in the imipenem-cilastatin plus 
placebo cohort. Entasis Therapeutics plans to initiate a Phase 
III study focused on CRAB infections in the first quarter of 2019 
[111].
TP-271 
TP-271 is a novel, fully-synthetic fluorocycline antibiotic under 
the development by Tetraphase Pharmaceuticals for treatment 
of CABP, pneumonic tularemia, and other serious respiratory 
bacterial/bio threat infections [112,113]. When the most 
common tetracycline-specific mechanisms are present, efflux 
pumps and ribosomal protection proteins, TP271 remains 
active in vitro [114]. When evaluated against four CRAB 
isolates in a neutropenic lung mouse model, TP271 was dose-
dependent with area under the curve (AUC) to MIC ratio best 
correlating with efficacy.  This  study  supported  the  future 
research  in  respiratory  infections  including  A. baumannii 
infections. A phase I study of escalating doses was well tolerated 
with gastrointestinal symptoms being most frequently reported 
[112]. Additionally, there are two ongoing phase I studies 
assessing single and multiple ascending doses of an oral 
formulation [115,116].
TP-6076 
Another novel, fully synthetic tetracycline is currently 
in phase I studies. It has a similar mechanism of action to 
tetracyclines in which it disrupts bacterial synthesis by binding 
to the 30S ribosomal subunit. In vitro data have shown potent 
activity against CRAB isolates with many containing OXA and 
OXA-like β-lactamases [117-120]. In the largest of these studies 
with 326 global isolates from the years 2005-2016, TP-6076 
had MIC50 and MIC90 values of 0.06 μg/mL and 0.125 μg/
mL while eravacycline had values of 0.5 μg/mL and 1 μg/mL, 
respectively (Table 1) [119]. TP-6076 did not demonstrate 
higher MIC values when comparing colistin-susceptible and 
non-susceptible isolates. However, the MIC90 was one dilution 
lower for tigecycline- and minocycline-susceptible and non-
susceptible isolates [117]. In isolates overexpressing genes 
encoding the AdeABC multidrug efflux pump, the major 
contributor to tigecycline resistance, TP-6076 had an MIC 
range of 0.008 to 0.13 μg/mL [118]. Gastrointestinal events 
(nausea and vomiting)  were  the  most  frequently reported 
adverse  event  with  higher  rates  at  the  higher doses [121]. A 
second   phase   I   study   is   currently   recruiting   to   assess 
the   safety   and bronchopulmonary PK with a dose of 30 mg 
daily [122]. With very little data, it seems as if TP-6076 is 
minimally impacted by the major resistance mechanisms of 
the tetracycline class with MICs mostly unaffected by serine-
dependent β-lactamases.
VNRX-5133 + cefepime 
Combined with cefepime, VNRX-5133 is a cyclic boronate 
β- lactamase inhibitor with broad-spectrum activity against 
serine- (classes A, C, and D) and metallo-β-lactamases (VIM/
NDM, class B). This combination agent is primarily being 
explored for CRE and CR Pseudomonas aeruginosa. In vitro 
data describes VNRX-5133/cefepime as a highly active agent 
against Enterobacteriaceae and P. aeruginosa that is resistant 
or has evolved resistance to other β-lactam/ β-lactamase 
inhibitors, however, its use against A. baumannii has not been 
described [123].
Zidebactam  (WCK  5107),  WCK  5153,  cefepime/zidebactam  
(WCK  5222)  
Zidebactam (WCK  5107)  and  WCK5153  are  novel  non-β-
lactamase  bicyclo-acyl  hydrazide  β-lactam enhancer antibiotics 
that are under development for MDR Enterobacteriaceae, 
P. aeruginosa, and CRAB [124]. These novel agents have a 
dual mechanism of action where they enhance β- lactams 
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through complementary high-affinity binding to PBP2 while 
strongly inhibiting class A and C β-lactamases along with 
modest inhibition of Class D β-lactamases. When zidebactam 
is combined with cefepime (WCK 5222) in vitro against 5946 
Enterobacteriaceae isolates, the combination demonstrated 
potent activity even against CR isolates. However, the MIC 
range of 639 A. baumannii isolates was 0.06 μg/mL to > 64 
μg/mL with only 44.3% of isolates having a MIC < 8 μg/mL 
[125]. These are less than optimal in vitro results against A. 
baumannii isolates, yet in vivo activity against OXA-23 or OXA-
24 isolates in a neutropenic thigh model and lung infection 
model showed greater than expected results [110,126].
WCK 5222 has been well tolerated in Phase I studies in subjects 
with both normal and impaired renal dysfunction [127,128]. 
Both agents are highly renally eliminated and will require dose 
adjustments based on the severity of dysfunction [127]. The 
pharmacodynamic property predicting therapeutic response for 
WCK 5222 is the free drug concentration in plasma exceeding 
the MIC over the dosing interval (Tf   > MIC). In subjects with 
normal renal function receiving multiple doses  of  either  2  g/1 
g  or  2  g/2  g  of  cefepime/zidebactam,  AUC  and  maximum 
serum concentration  (Cmax)  were  dose  proportional,  no 
accumulation  occurred,  and  no pharmacokinetic interaction 
was observed when co-administered [128]. Phase I studies 
evaluating plasma and lung tissue provided data to support the 
use of WCK 5222 in the treatment of pneumonia, while other 
organ systems have yet to be evaluated [129].
Other Antibiotics
AIC-499 (BL) + unknown BLI 
AIC499 is termed as an innovative β-lactam antibiotic and is 
combined with a currently unspecified β-lactamase inhibitor. 
According to the drug developer’s website, AIC499 shows 
potent activity against many Gram-negative pathogens 
including MDR P. aeruginosa and A. baumannii for use in 
cUTI and cIAI. Phase I studies were expecting results in 2017 
with plans for future phase II studies, however, no trials are 
currently registered on multiple government trial registries. 
The phase I study was to be a single dose study in 48 
healthy subjects immediately followed by a multiple ascending 
dose study in 36 subjects at the Medical   University   of   Vienna, 
Austria.   The   Innovative   Medicines   Initiative   with   the 
COMBACTE-MAGNET project is supporting AiCuris in the 
clinical development of AIC499 [130].
GSK3342830 (GSK830) 
GSK3342830 or GSK830 is a catechol-cephalosporin with a 
spectrum of activity similar to that of the other siderophore 
cephalosporin, cefiderocol [131]. In vitro data are promising 
against A. baumannii with 94 MDR global isolates having 
MIC50 and MIC90  of 0.06 μg/mL and 0.6 μg/mL, respectively 
[131]. However, a phase I dose-escalation study was stopped 
early. It is important to note that 35.7% of subjects discontinued 
the study drug during the multi- dose arm due to fever, 
headache, malaise or transaminitis [132].
SPR741 (formerly NAB74) 
SPR741 (formerly NAB74) is a polymyxin-B-like molecule 
being developed as an antibiotic adjuvant for the treatment 
of XDR A. baumannii. This molecule does not have certain 
structural features of the polymyxins that contribute to their 
nephrotoxicity, however, this agent has minimal intrinsic 
activity against A. baumannii and must be used as combination 
therapy [133]. When  combined  with  rifampin  in  pre-clinical 
data  of  a  murine pneumonia model, this combination has 
shown to be effective in reducing bacterial burden (suggesting 
utility in A. baumannii lung infections) [133,134]. SPR741 has 
a short half-life of approximately 3 hours with 50% of the drug 
excreted in the urine within one-hour post-dose with no evidence 
of accumulation with 400 mg administered intravenously 
every 8 hours [135]. Other phase I studies have been completed 
in 2017; however, no results are available [136,137].
Novel Therapies
Monoclonal antibodies 
Antibacterial monoclonal antibodies (MAbs) have the ability 
to protect (e.g., palivizumab for prophylaxis against respiratory 
syncytial virus) and treat (e.g., obiltoxaximab for treatment 
of inhalational anthrax) against deadly infections. MAbs 
are highly specific and may lessen the disruption of normal 
gastrointestinal flora with less selective pressure for cross- 
resistance with antibiotics [138]. Additionally, antibacterial 
MAbs could have an enormous impact on controlling 
institutional outbreaks once the pathogen is known. However, 
aside from their narrow spectrum, there are concerns 
surrounding the use of MAb therapy in infectious diseases. 
Notably, these include high cost, complex administration, and 
barriers to MAb development [139].
Several studies have shown MAb efficacy against A. baumannii 
in mice when provided as active immunization (i.e., vaccine) 
and passive immunization in various models [140-143]. Most 
recently, a MAb, C8 in an A. baumannii mice pneumonia and 
sepsis model demonstrated enhanced bacterial clearance, 
prevented progression to septic shock, and had synergistic 
activity with colistin. An area of concern in this study was the 
ability of C8 to bind to only 60% of A. baumannii strains tested 
[144].
Phage therapy 
As A. baumannii resistance continues to increase and the 
portfolio of antibiotics is becoming increasingly less effective, 
bacteriophage therapy becomes an alluring option. Termed 
“phage,” this technology is simply a virus engineered to infect a 
pathogenic bacterium, replicate inside the host cell, and finally 
rupture the bacterial cell wall resulting in cell death [145]. 
Similarly to  MAbs,  phage  are  highly  specific,  infecting  only 
prokaryotic  cells  resulting  in minimal toxicities and side effects 
[146]. Additionally, their mechanism of action is completely 
independent of antibiotics so their efficacy is not altered 
against highly resistant bacteria [147]. Other advantages of 
this technology include the potential for combinations with 
traditional therapies [148]. However, numerous questions about 
this therapy remain. This therapy is not currently recognized as 
a drug and a clear lack of regulatory framework exists [145,149]. 
Because it is given in high quantities, the human body may 
recognize phage as foreign antigens, produce antibodies, 
and theoretically result in a diminished activity. Finally, the 
possibility of horizontal gene transfer can occur resulting in 
the transfer of resistance genes and virulence factors between 
bacterium and phage [146].
Numerous studies (n=30) with a total of 1,152 patients have been 
conducted to evaluate the efficacy and safety of phage therapy 
against ESKAPE pathogens. Of the 30 studies, 87% showed 
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efficacy of reducing bacterial growth with successful outcomes. 
Twenty-two studies reported on the safety profile with only two 
reporting side effects after phage treatment [147]. Regarding 
A. baumannii specific infections, several animal models have 
been conducted in MDR and CRAB isolates with promising 
results [150-155]. To date, only two human case reports of 
phage therapy directed against MDR A. baumannii have been 
published [156,157]. The first describes a case of a 68-year-old 
diabetic patient with necrotizing pancreatitis complicated by an 
MDR A. baumannii infection. In conjunction with combination 
antibiotics, three phage cocktails were provided intravenously 
and percutaneously into the abscessed cavity in repeated daily 
intervals for a total of 59 days. The patient’s initial status was 
improved after commencing phage therapy with an eventual 
return to health. Interestingly, however, subsequent cultures 
were obtained with strains showing reduced susceptibility to 
phage therapy [157]. The second case report describes a 77-
year- old traumatic brain injury patient undergoing craniectomy 
complicated by cerebritis and subdural and epidural empyemas. 
Debridement was deemed necessary and intraoperative 
cultures grew MDR A. baumannii. In addition to antibiotics, 
the first dose of phage therapy was administered intravenously 
on day 12 and continued for 8 days (98 intravenous 
administrations). While the site of infection healed, the patient 
did not clinically improve and family withdrew care on hospital 
day 19 [156].
Conclusion
Acinetobacter  baumannii  has  the  extraordinary  adaptive 
ability  to  develop  resistance  to overcome all treatment 
options currently available. Despite the promising focus in 
recent years on developing novel therapies, more real-world 
experience in critically ill patients with invasive MDR A. 
baumannii infections is needed to solidify a place in therapy for 
one or more of these novel therapies. Moreover, many of these 
novel antimicrobials have already demonstrated vulnerability 
as reports of increasing MICs have been observed. Despite these 
challenges, novel treatment modalities for MDR A. baumannii 
are encouraging, yet further advances will be required as the era 
of antimicrobial resistance continues.
Declarations of Potential Conflict of 
Interest
The authors declare that they have no competing interests.
Funding
The authors received no specific funding for this work.
References
1. Lynch JP 3rd, Zhanel GG, Clark NM. Infections due to 
Acinetobacter baumannii in the ICU: treatment options. 
Semin Respir Crit Care Med. 2017 Jun;38(3):311–25. 
2. Rhomberg PR, Jones RN. Summary trends for the 
Meropenem Yearly Susceptibility Test Information 
Collection Program: a 10-year experience in the United 
States (1999-2008). Diagn Microbiol Infect Dis. 2009 
Dec;65(4):414–26. 
3. Centers for Disease Control and Prevention (US). Antibiotic 
resistance threats in the United States, 2013. Centres for 
Disease Control and Prevention, US Department of Health 
and Human Services; 2013.
4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert 
D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An 
update from the Infectious Diseases Society of America. 
Clin Infect Dis. 2009 Jan;48(1):1–12. 
5. Alfouzan WA, Noel AR, Bowker KE, Attwood ML, 
Tomaselli SG, MacGowan AP. Pharmacodynamics of 
minocycline against Acinetobacter baumannii studied in 
a pharmacokinetic model of infection. Int J Antimicrob 
Agents. 2017 Dec;50(6):715–7. 
6. Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu 
JW, et al. A multicenter study of risk factors and outcome 
of hospitalized patients with infections due to carbapenem-
resistant Acinetobacter baumannii. Int J Infect Dis. 2010 
Sep;14(9):e764–9. 
7. Playford EG, Craig JC, Iredell JR. Carbapenem-
resistant Acinetobacter baumannii in intensive care unit 
patients: risk factors for acquisition, infection and their 
consequences. J Hosp Infect. 2007 Mar;65(3):204–11. 
8. World Health Organization. WHO publishes priority 
list of antibiotic-resistant pathogens. WHO Drug Inf. 
2017;31(1):46.
9. Simpkin VL, Renwick MJ, Kelly R, Mossialos E. 
Incentivising innovation in antibiotic drug discovery 
and development: progress, challenges and next steps. J 
Antibiot (Tokyo). 2017 Dec;70(12):1087–96. 
10. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, 
Falagas ME, Giske CG, et al. Multidrug-resistant, 
extensively drug-resistant and pandrug-resistant bacteria: 
an international expert proposal for interim standard 
definitions for acquired resistance. Clin Microbiol Infect. 
2012 Mar;18(3):268–81. 
11. Peleg AY, Seifert H, Paterson DL. Acinetobacter 
baumannii: emergence of a successful pathogen. Clin 
Microbiol Rev. 2008 Jul;21(3):538–82. 
12. Nowak J, Zander E, Stefanik D, Higgins PG, Roca I, 
Vila J, et al. MagicBullet Working Group WP4. High 
incidence of pandrug-resistant Acinetobacter baumannii 
isolates collected from patients with ventilator-associated 
pneumonia in Greece, Italy and Spain as part of the 
MagicBullet clinical trial. J Antimicrob Chemother. 2017 
Dec;72(12):3277–82. 
13. Bonomo RA, Szabo D. Mechanisms of multidrug resistance 
in Acinetobacter species and Pseudomonas aeruginosa. 
Clin Infect Dis. 2006 Sep 1;43(Supplement_2):S49-56.
14. Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter 
baumannii: from bench to bedside. World J Clin Cases. 
2014 Dec;2(12):787–814. 
15. Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, et 
al. Biology of Acinetobacter baumannii: pathogenesis, 
antibiotic resistance mechanisms, and prospective 
treatment options. Front Cell Infect Microbiol. 2017 
Mar;7:55. 
16. Castanheira M, Mendes RE, Jones RN. Update on 
Acinetobacter species: mechanisms of antimicrobial 
resistance and contemporary in vitro activity of 
minocycline and other treatment options. Clin Infect Dis. 
2014 Dec 1;59(suppl_6):S367-73.
17. Vilacoba E, Almuzara M, Gulone L, Traglia GM, Figueroa 
SA, Sly G, et al. Emergence and spread of plasmid-borne 
tet(B):ISCR2 in minocycline-resistant Acinetobacter 
baumannii isolates. Antimicrob Agents Chemother. 2013 
Jan;57(1):651–4. 
10ULJRI Vol 3, (2) 2019
18. Wang P, McElheny CL, Mettus RT, Shanks RM, Doi Y. 
Contribution of the TetB efflux pump to minocycline 
susceptibility among carbapenem-resistant Acinetobacter 
baumannii strains. Antimicrob Agents Chemother. 2017 
Sep;61(10):e01176-17. 
19. He X, Lu F, Yuan F, Jiang D, Zhao P, Zhu J, et al. Biofilm 
formation caused by clinical Acinetobacter baumannii 
isolates is associated with overexpression of the AdeFGH 
Efflux Pump. Antimicrob Agents Chemother. 2015 
Aug;59(8):4817–25. 
20. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano 
B, et al. Acinetobacter baumannii bloodstream infection 
while receiving tigecycline: a cautionary report. J 
Antimicrob Chemother. 2007 Jan;59(1):128–31. 
21. Moffatt JH, Harper M, Harrison P, Hale JD, 
Vinogradov E, Seemann T, et al. Colistin resistance in 
Acinetobacter baumannii is mediated by complete loss 
of lipopolysaccharide production. Antimicrob Agents 
Chemother. 2010 Dec;54(12):4971–7. 
22. Duarte A, Ferreira S, Almeida S, Domingues FC. Clinical 
isolates of Acinetobacter baumannii from a Portuguese 
hospital: PFGE characterization, antibiotic susceptibility 
and biofilm-forming ability. Comp Immunol Microbiol 
Infect Dis. 2016 Apr;45:29–33. 
23. Eze EC, Chenia HY, El Zowalaty ME. Acinetobacter 
baumannii biofilms: effects of physicochemical factors, 
virulence, antibiotic resistance determinants, gene 
regulation, and future antimicrobial treatments. Infect 
Drug Resist. 2018 Nov;11:2277–99. 
24. Rhodes NJ, Cruce CE, O’Donnell JN, Wunderink RG, 
Hauser AR. Resistance trends and treatment options in 
Gram-negative ventilator-associated pneumonia. Curr 
Infect Dis Rep. 2018 Mar;20(2):3. 
25. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel 
J, Kallen AJ, et al. Antimicrobial-resistant pathogens 
associated with healthcare-associated infections: 
summary of data reported to the National Healthcare 
Safety Network at the Centers for Disease Control and 
Prevention, 2011-2014. Infect Control Hosp Epidemiol. 
2016 Nov;37(11):1288–301. 
26. Mehrad B, Clark NM, Zhanel GG, Lynch JP 3rd. 
Antimicrobial resistance in hospital-acquired Gram-
negative bacterial infections. Chest. 2015 May;147(5):1413–
21. 
27. Xie R, Zhang XD, Zhao Q, Peng B, Zheng J. Analysis of 
global prevalence of antibiotic resistance in Acinetobacter 
baumannii infections disclosed a faster increase in OECD 
countries. Emerg Microbes Infect. 2018 Mar;7(1):31–10. 
28. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new 
lessons on an old antibiotic. Clin Microbiol Infect. 2012 
Jan;18(1):18–29. 
29. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins 
revisited. Clin Microbiol Rev. 2008 Jul;21(3):449–65. 
30. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, 
Forrest A, et al. International Consensus Guidelines 
for the Optimal Use of the Polymyxins: Endorsed by the 
American College of Clinical Pharmacy (ACCP), European 
Society of Clinical Microbiology and Infectious Diseases 
(ESCMID), Infectious Diseases Society of America (IDSA), 
International Society for Anti-infective Pharmacology 
(ISAP), Society of Critical Care Medicine (SCCM), and 
Society of Infectious Diseases Pharmacists (SIDP). 
Pharmacotherapy. 2019 Jan;39(1):10–39. 
31. Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation 
RL. Colistin and polymyxin B dosage regimens against 
Acinetobacter baumannii: differences in activity and the 
emergence of resistance. Antimicrob Agents Chemother. 
2016 Jun;60(7):3921–33. 
32. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, 
Massih RC, et al. Epidemiology, clinical characteristics 
and outcomes of extensively drug-resistant Acinetobacter 
baumannii infections among solid organ transplant 
recipients. PLoS One. 2012;7(12):e52349. 
33. Snitkin ES, Zelazny AM, Gupta J, Palmore TN, Murray 
PR, Segre JA; NISC Comparative Sequencing Program. 
Genomic insights into the fate of colistin resistance and 
Acinetobacter baumannii during patient treatment. 
Genome Res. 2013 Jul;23(7):1155–62. 
34. Lim SM, Sime FB, Roberts J. Multidrug-resistant 
Acinetobacter baumannii infections: current evidence on 
treatment options and role of PK/PD in dose optimization. 
Int J Antimicrob Agents. 2019 Mar 2.
35. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance 
of Acinetobacter baumannii: clinical reports, mechanisms 
and antimicrobial strategies. J Antimicrob Chemother. 
2012 Jul;67(7):1607–15. 
36. Vazquez Guillamet C, Kollef MH. Acinetobacter 
pneumonia: improving outcomes with early identification 
and appropriate therapy. Clin Infect Dis. 2018 
Oct;67(9):1455–62. 
37. Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed 
A, Shields RK, et al. Colistin-resistant Acinetobacter 
baumannii: beyond carbapenem resistance. Clin Infect 
Dis. 2015 May;60(9):1295–303. 
38. Zarkotou O, Pournaras S, Voulgari E, Chrysos G, Prekates 
A, Voutsinas D, et al. Risk factors and outcomes associated 
with acquisition of colistin-resistant KPC-producing 
Klebsiella pneumoniae: a matched case-control study. J 
Clin Microbiol. 2010 Jun;48(6):2271–4. 
39. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. 
Ampicillin/sulbactam compared with polymyxins for the 
treatment of infections caused by carbapenem-resistant 
Acinetobacter spp. J Antimicrob Chemother. 2008 
Jun;61(6):1369–75. 
40. Zalts R, Neuberger A, Hussein K, Raz-Pasteur A, 
Geffen Y, Mashiach T, et al. Treatment of carbapenem-
resistant Acinetobacter baumannii ventilator-associated 
pneumonia: retrospective comparison between 
intravenous colistin and intravenous ampicillin-sulbactam. 
Am J Ther. 2016 Jan-Feb;23(1):e78–85. 
41. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez 
FJ, Barrero-Almodóvar AE, García-Garmendia JL, 
Bernabeu-WittelI M, et al. Treatment of multidrug-
resistant Acinetobacter baumannii ventilator-associated 
pneumonia (VAP) with intravenous colistin: a comparison 
with imipenem-susceptible VAP. Clin Infect Dis. 2003 
May;36(9):1111–8. 
42. Beganovic M, Luther MK, Daffinee KE, LaPlante KL. 
Biofilm prevention concentrations (BPC) of minocycline 
compared to polymyxin B, meropenem, and amikacin 
against Acinetobacter baumannii. Diagn Microbiol Infect 
Dis. 2019 Jul;94(3):223–6. 
43. Denys GA, Callister SM, Dowzicky MJ. Antimicrobial 
susceptibility among Gram-negative isolates collected in 
the USA between 2005 and 2011 as part of the Tigecycline 
Evaluation and Surveillance Trial (T.E.S.T.). Ann Clin 
Microbiol Antimicrob. 2013 Sep;12(1):24. 
44. Hoban DJ, Reinert RR, Bouchillon SK, Dowzicky MJ. 
Global in vitro activity of tigecycline and comparator 
agents: Tigecycline Evaluation and Surveillance Trial 
11ULJRI Vol 3, (2) 2019
2004-2013. Ann Clin Microbiol Antimicrob. 2015 
May;14(1):27. 
45. Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, 
Mediavilla JR, et al. Informing antibiotic treatment 
decisions: evaluating rapid molecular diagnostics to 
identify susceptibility and resistance to carbapenems 
against Acinetobacter spp. in PRIMERS III. J Clin 
Microbiol. 2016 Dec;55(1):134–44. 
46. Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and 
clinical outcomes of carbapenem-resistant Acinetobacter 
baumannii ventilator-associated pneumonia. J Intensive 
Care Med. 2010 Nov-Dec;25(6):343–8. 
47. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik 
O, Glumcher F, et al.; 311 Study Group. Comparison of 
tigecycline with imipenem/cilastatin for the treatment of 
hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 
2010 Oct;68(2):140–51. 
48. Marchaim D, Pogue JM, Tzuman O, Hayakawa K, Lephart 
PR, Salimnia H, et al. Major variation in MICs of tigecycline 
in Gram-negative bacilli as a function of testing method. J 
Clin Microbiol. 2014 May;52(5):1617–21. 
49. Wayne PA. Clinical and Laboratory Standards Institute: 
Performance standards for antimicrobial susceptibility 
testing: 20th informational supplement. CLSI document 
M100-S20. 2010.
50. Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R. The emergence 
of clinical resistance to tigecycline. Int J Antimicrob 
Agents. 2013 Feb;41(2):110–6. 
51. Ni W, Han Y, Zhao J, Wei C, Cui J, Wang R, et al. 
Tigecycline treatment experience against multidrug-
resistant Acinetobacter baumannii infections: a systematic 
review and meta-analysis. Int J Antimicrob Agents. 2016 
Feb;47(2):107–16. 
52. Evans BA, Hamouda A, Amyes SG. The rise of carbapenem-
resistant Acinetobacter baumannii. Curr Pharm Des. 
2013;19(2):223–38. 
53. Buisson Y, Tran Van Nhieu G, Ginot L, Bouvet P, Schill 
H, Driot L, et al. Nosocomial outbreaks due to amikacin-
resistant tobramycin-sensitive Acinetobacter species: 
correlation with amikacin usage. J Hosp Infect. 1990 
Jan;15(1):83–93. 
54. Barnes MD, Bethel CR, Rutter JD, Akker FV, Papp-Wallace 
KM, Bonomo RA. The novel β-Lactamase inhibitor, ETX-
2514, in combination with sulbactam effectively inhibits 
Acinetobacter baumannii. In Open forum infectious 
diseases 2017 Oct 4 (Vol. 4, No. suppl_1, pp. S368-S368). 
US: Oxford University Press.
55. Chen H, Liu Q, Chen Z, Li C. Efficacy of sulbactam for 
the treatment of Acinetobacter baumannii complex 
infection: A systematic review and meta-analysis. J Infect 
Chemother. 2017 May;23(5):278–85. 
56. Bae S, Kim MC, Park SJ, Kim HS, Sung H, Kim MN, et 
al. In vitro synergistic activity of antimicrobial agents in 
combination against clinical isolates of colistin-resistant 
Acinetobacter baumannii. Antimicrob Agents Chemother. 
2016 Oct;60(11):6774–9. 
57. Chen Z, Chen Y, Fang Y, Wang X, Chen Y, Qi Q, et al. Meta-
analysis of colistin for the treatment of Acinetobacter 
baumannii infection. Sci Rep. 2015 Nov;5(1):17091. 
58. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, 
De Cristoforo M, Murino P, et al. Colistin and rifampicin 
compared with colistin alone for the treatment of serious 
infections due to extensively drug-resistant Acinetobacter 
baumannii: a multicenter, randomized clinical trial. Clin 
Infect Dis. 2013 Aug;57(3):349–58. 
59. Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli 
Y, Benattar YD, et al. Colistin alone versus colistin plus 
meropenem for treatment of severe infections caused by 
carbapenem-resistant Gram-negative bacteria: an open-
label, randomised controlled trial. Lancet Infect Dis. 2018 
Apr;18(4):391–400. 
60. Makris D, Petinaki E, Tsolaki V, Manoulakas E, Mantzarlis 
K, Apostolopoulou O, et al. Colistin versus colistin 
combined with ampicillin-sulbactam for multiresistant 
Acinetobacter baumannii ventilator-associated 
pneumonia treatment: an open-label prospective study. 
Indian J Crit Care Med. 2018 Feb;22(2):67–77. 
61. Sirijatuphat R, Thamlikitkul V. Preliminary study of 
colistin versus colistin plus fosfomycin for treatment 
of carbapenem-resistant Acinetobacter baumannii 
infections. Antimicrob Agents Chemother. 2014 
Sep;58(9):5598–601. 
62. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, 
Terzi A, et al. Colistin vs. the combination of colistin 
and rifampicin for the treatment of carbapenem-
resistant Acinetobacter baumannii ventilator-associated 
pneumonia. Epidemiol Infect. 2013 Jun;141(6):1214–22. 
63. Cheng IL, Chen YH, Lai CC, Tang HJ. Intravenous 
colistin monotherapy versus combination therapy against 
carbapenem-resistant Gram-negative bacteria infections: 
meta-analysis of randomized controlled trials. J Clin Med. 
2018 Aug;7(8):208. 
64. Shin JA, Chang YS, Kim HJ, Kim SK, Chang J, Ahn CM, 
et al. Clinical outcomes of tigecycline in the treatment of 
multidrug-resistant Acinetobacter baumannii infection. 
Yonsei Med J. 2012 Sep;53(5):974–84. 
65. Tasbakan MS, Pullukcu H, Sipahi OR, Tasbakan MI, 
Aydemir S, Bacakoglu F. Is tigecyclin a good choice in the 
treatment of multidrug-resistant Acinetobacter baumannii 
pneumonia? J Chemother. 2011 Dec;23(6):345–9. 
66. Kim WY, Moon JY, Huh JW, Choi SH, Lim CM, Koh Y, 
et al. Comparable efficacy of tigecycline versus colistin 
therapy for multidrug-resistant and extensively drug-
resistant Acinetobacter baumannii pneumonia in critically 
ill patients. PLoS One. 2016 Mar;11(3):e0150642. 
67. Lee YT, Tsao SM, Hsueh PR. Clinical outcomes of tigecycline 
alone or in combination with other antimicrobial agents 
for the treatment of patients with healthcare-associated 
multidrug-resistant Acinetobacter baumannii infections. 
Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1211–20. 
68. Jean SS, Hsieh TC, Hsu CW, Lee WS, Bai KJ, Lam C. 
Comparison of the clinical efficacy between tigecycline 
plus extended-infusion imipenem and sulbactam plus 
imipenem against ventilator-associated pneumonia with 
pneumonic extensively drug-resistant Acinetobacter 
baumannii bacteremia, and correlation of clinical efficacy 
with in vitro synergy tests. J Microbiol Immunol Infect. 
2016 Dec 1;49(6):924-33.
69. He H, Zheng Y, Sun B, Tang X, Wang R, Tong Z. Tigecycline 
combination for ventilator-associated pneumonia caused 
by extensive drug-resistant Acinetobacter baumannii. J 
Thorac Dis. 2016 Oct;8(10):2784–92. 
70. Liang CA, Lin YC, Lu PL, Chen HC, Chang HL, Sheu CC. 
Antibiotic strategies and clinical outcomes in critically ill 
patients with pneumonia caused by carbapenem-resistant 
Acinetobacter baumannii. Clin Microbiol Infect. 2018 
Aug;24(8):908.e1–7. 
71. Goff DA, Bauer KA, Mangino JE. Bad bugs need old 
drugs: a stewardship program’s evaluation of minocycline 
for multidrug-resistant Acinetobacter baumannii 
12ULJRI Vol 3, (2) 2019
infections. Clinical Infectious Diseases. 2014 Dec 
1;59(suppl_6):S381-7.
72. Craig WA. Pharmacokinetic/pharmacodynamic 
parameters: rationale for antibacterial dosing of mice and 
men. Clin Infect Dis. 1998 Jan;26(1):1–10. 
73. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of 
area under the inhibitory curve (AUIC) and time above 
the minimum inhibitory concentration (T>MIC) as 
predictors of outcome for cefepime and ceftazidime in 
serious bacterial infections. Int J Antimicrob Agents. 2008 
Apr;31(4):345–51. 
74. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova 
T, et al. Clinical and microbiological efficacy of continuous 
versus intermittent application of meropenem in critically 
ill patients: a randomized open-label controlled trial. Crit 
Care. 2012 Jun;16(3):R113. 
75. Yu Z, Pang X, Wu X, Shan C, Jiang S. Clinical outcomes 
of prolonged infusion (extended infusion or continuous 
infusion) versus intermittent bolus of meropenem in 
severe infection: A meta-analysis. PLoS One. 2018 
Jul;13(7):e0201667. 
76. Wang D. Experience with extended-infusion meropenem 
in the management of ventilator-associated pneumonia 
due to multidrug-resistant Acinetobacter baumannii. Int J 
Antimicrob Agents. 2009 Mar;33(3):290–1. 
77. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek 
ST, Kollef MH. Predictors of 30-day mortality and hospital 
costs in patients with ventilator-associated pneumonia 
attributed to potentially antibiotic-resistant Gram-
negative bacteria. Chest. 2008 Aug;134(2):281–7. 
78. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley 
J, McGovern PC. Randomized phase 2 trial to evaluate the 
clinical efficacy of two high-dosage tigecycline regimens 
versus imipenem-cilastatin for treatment of hospital-
acquired pneumonia. Antimicrob Agents Chemother. 2013 
Apr;57(4):1756–62. 
79. De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, 
Bello G, et al. High dose tigecycline in critically ill patients 
with severe infections due to multidrug-resistant bacteria. 
Crit Care. 2014 May;18(3):R90. 
80. Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden 
A, Schweizer F, et al. Review of eravacycline, a 
novel fluorocycline antibacterial agent. Drugs. 2016 
Apr;76(5):567–88. 
81. Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky 
JA. In vitro activity of eravacycline against 2213 Gram-
negative and 2424 Gram-positive bacterial pathogens 
isolated in Canadian hospital laboratories: CANWARD 
surveillance study 2014-2015. Diagn Microbiol Infect Dis. 
2018 May;91(1):55–62. 
82. Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro 
activity of the novel fluorocycline eravacycline against 
carbapenem non-susceptible Acinetobacter baumannii. 
Int J Antimicrob Agents. 2018 Jan;51(1):62–4. 
83. Livermore DM, Mushtaq S, Warner M, Woodford N. In 
vitro activity of eravacycline against carbapenem-resistant 
Enterobacteriaceae and Acinetobacter baumannii. 
Antimicrob Agents Chemother. 2016 May;60(6):3840–4. 
84. Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, 
Quale J. Activity of eravacycline against Enterobacteriaceae 
and Acinetobacter baumannii, including multidrug-
resistant isolates, from New York City. Antimicrob Agents 
Chemother. 2015 Mar;59(3):1802–5. 
85. Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai 
L, et al. Assessing the efficacy and safety of eravacycline vs 
ertapenem in complicated intra-abdominal infections in 
the investigating Gram-negative infections treated with 
eravacycline (IGNITE 1) trial: a randomized clinical trial. 
JAMA Surg. 2017 Mar;152(3):224–32. 
86. Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, 
Stefanova P, Sutcliffe JA, et al. Phase 2, randomized, double-
blind study of the efficacy and safety of two dose regimens 
of eravacycline versus ertapenem for adult community-
acquired complicated intra-abdominal infections. 
Antimicrob Agents Chemother. 2014;58(4):1847–54. 
87. Tetraphase Pharmaceuticals. Tetraphase announces 
positive top-line results from phase 3 IGNITE4 clinical 
trial in complicated intra-abdominal infections [press 
release] (2017 Jul 25) [cited 2019 Sep 30]. Available 
from: https://ir.tphase.com/news-releases/news-release-
details/tetraphase-announces-positive-top-line-results-
phase-3-ignite4
88. ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2000 Feb 29 - . Identifier 
NCT03696550, A safety and PK study of IV eravacycline; 
2018 Sep 26 [cited 2019 Sep 30]; [about 8 screens]. 
Available from: https://clinicaltrials.gov/ct2/show/
NCT03696550
89. Yue CS, Sutcliffe JA, Colucci P, Sprenger CR. Population 
pharmacokinetic modeling of TP-434, a novel fluorocycline, 
following single and multiple dose administration. 
Abstract presented at: 50th Interscience Conference of 
Antimicrobial Agents and Chemotherapy (ICAAC); 2010 
Sep 12-15; Boston, MA.
90. Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: 
Results of a phase 3, randomized, multicenter, prospective 
trial of eravacycline vs meropenem in the treatment of 
complicated intraabdominal infections. Clin Infect Dis. 
2018 Dec 1.
91. Tetraphase Pharmaceuticals. Tetraphase announces 
top-line results from IGNITE3 phase 3 clinical trial of 
eravacycline in complicated urinary tract infections (cUTI) 
[press release] (2018 Feb 13) [cited 2018 Dec 18]. Available 
from: https://ir.tphase.com/news-releases/news-release-
details/tetraphase-announces-top-line-results-ignite3-
phase-3-clinical
92. Pfaller MA, Huband MD, Rhomberg PR, Flamm RK. 
Surveillance of omadacycline activity against clinical 
isolates from a global collection (North America, 
Europe, Latin America, Asia-Western Pacific), 
2010-2011. Antimicrob Agents Chemother. 2017 
Apr;61(5):e00018–00017. 
93. Pfaller MA, Huband MD, Shortridge D, Flamm RK. 
Surveillance of omadacycline activity tested against clinical 
isolates from the United States and Europe as part of 
the 2016 SENTRY Antimicrobial Surveillance Program. 
Antimicrob Agents Chemother. 2018 Mar;62(4):e02327-17. 
94. Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej 
A, et al. Omadacycline for community-acquired bacterial 
pneumonia. N Engl J Med. 2019 Feb;380(6):517–27. 
95. O’Riordan W, Green S, Overcash JS, Puljiz I, Metallidis 
S, Gardovskis J, et al. Omadacycline for acute bacterial 
skin and skin-structure infections. N Engl J Med. 2019 
Feb;380(6):528–38. 
96. Xerava (eravacycline) for injection [package insert on the 
Internet]. Watertown (MA): Tetraphase Pharmaceuticals, 
2018 [revised 2018 Aug; cited 2018 Dec 18]. Available 
from: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2018/211109lbl.pdf
97. Tygacil (tigecycline) i.v. injection label [package insert on 
13ULJRI Vol 3, (2) 2019
the Internet]. Philadelphia (PA): Wyeth Pharmaceuticals 
Inc., 2010 [revised 2010 Jul; cited 2018 Dec 15]. Available 
from: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2010/021821s021lbl.pdf
98. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, 
Sahm DF. In vitro activity of the siderophore cephalosporin, 
cefiderocol, against carbapenem-nonsusceptible and 
multidrug-resistant isolates of Gram-negative bacilli 
collected worldwide in 2014 to 2016. Antimicrob Agents 
Chemother. 2018 Jan;62(2):e01968-17. 
99. Möllmann U, Heinisch L, Bauernfeind A, Köhler T, 
Ankel-Fuchs D. Siderophores as drug delivery agents: 
application of the “Trojan Horse” strategy. Biometals. 
2009 Aug;22(4):615–24. 
100. Aoki T, Yoshizawa H, Yamawaki K, Yokoo K, Sato 
J, Hisakawa S, et al. Cefiderocol (S-649266), A new 
siderophore cephalosporin exhibiting potent activities 
against Pseudomonas aeruginosa and other Gram-
negative pathogens including multi-drug resistant 
bacteria: structure activity relationship. Eur J Med Chem. 
2018 Jul;155:847–68. 
101. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, 
Sahm DF. In vitro activity of the siderophore cephalosporin, 
cefiderocol, against a recent collection of clinically relevant 
Gram- negative bacilli from North America and Europe, 
including carbapenem-nonsusceptible isolates (SIDERO-
WT-2014 Study). Antimicrob Agents Chemother. 2017 
Aug;61(9):e00093-17. 
102. Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, 
Sahm DF. In vitro activity of cefiderocol, a siderophore 
cephalosporin, against Gram-negative bacilli isolated by 
clinical laboratories in North America and Europe in 2015-
2016: SIDERO-WT-2015. Int J Antimicrob Agents. 2019 
Apr;53(4):456–66. 
103. Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR. 
In vitro activities of cefiderocol, ceftolozane/tazobactam, 
ceftazidime/avibactam and other comparative drugs 
against imipenem-resistant Pseudomonas aeruginosa 
and Acinetobacter baumannii, and Stenotrophomonas 
maltophilia, all associated with bloodstream infections in 
Taiwan. J Antimicrob Chemother. 2019 Feb;74(2):380–6. 
104. Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, 
Echols R, et al. In vitro activity of cefiderocol, a siderophore 
cephalosporin, against a recent collection of clinically 
relevant carbapenem-non-susceptible Gram-negative 
bacilli, including serine carbapenemase- and metallo-β-
lactamase-producing isolates (SIDERO-WT-2014 Study). 
Int J Antimicrob Agents. 2019 Feb;53(2):177–84. 
105. Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ; Hellenic 
Cefiderocol Study Group. Activity of cefiderocol (S-
649266) against carbapenem-resistant Gram-negative 
bacteria collected from inpatients in Greek hospitals. J 
Antimicrob Chemother. 2017 Jun;72(6):1704–8. 
106. Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg 
JK, Galloway C. Cefiderocol, a siderophore cephalosporin 
for Gram-negative bacterial infections; pharmacokinetics 
and safety in subjects with renal impairment. J Clin 
Pharmacol. 2017 May;57(5):584–91. 
107. Portsmouth S, van Veenhuyzen D, Echols R, Machida M, 
Ferreira JC, Ariyasu M, et al. Cefiderocol versus imipenem-
cilastatin for the treatment of complicated urinary tract 
infections caused by Gram-negative uropathogens: a phase 
2, randomised, double-blind, non-inferiority trial. Lancet 
Infect Dis. 2018 Dec;18(12):1319–28. 
108. Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, 
Bifulco N, Huynh H, et al. ETX2514 is a broad-spectrum 
β-lactamase inhibitor for the treatment of drug-resistant 
Gram-negative bacteria including Acinetobacter 
baumannii. Nat Microbiol. 2017 Jun;2(9):17104. 
109. Mushtaq S, Vickers A, Woodford N, Livermore DM. 
WCK 4234, a novel diazabicyclooctane potentiating 
carbapenems against Enterobacteriaceae, Pseudomonas 
and Acinetobacter with class A, C and D β-lactamases. J 
Antimicrob Chemother. 2017 Jun;72(6):1688–95. 
110. McLeod SM, Shapiro AB, Moussa SH, Johnstone M, 
McLaughlin RE, de Jonge BL, et al. Frequency and 
mechanism of spontaneous resistance to sulbactam 
combined with the novel β-lactamase inhibitor ETX2514 in 
clinical isolates of Acinetobacter baumannii. Antimicrob 
Agents Chemother. 2018 Jan;62(2):e01576-17. 
111. Tetraphase Pharmaceuticals. Tetraphase announces 
top-line results from IGNITE2 phase 3 clinical trial of 
eravacycline in cUTI [press release] (2015 Sep 8) [cited 
2019 Sep 30]. Available from: https://ir.tphase.com/news-
releases/news-release-details/tetraphase-announces-top-
line-results-ignite2-phase-3-clinical
112. Tetraphase Pharmaceuticals. Tetraphase Pharmaceuticals 
announces positive phase 1 single-ascending dose data for 
antibiotic pipeline candidates [press release] (2017 Jun 
5) [cited 2019 Sep 30]. Available from: https://ir.tphase.
com/news-releases/news-release-details/tetraphase-
pharmaceuticals-announces-positive-phase-1-single
113. Grossman TH, Fyfe C, O’Brien W, et al. Fluorocycline TP-
271 is potent against complicated community-acquired 
bacterial pneumonia pathogens. mSphere. 2017 Feb;22;(2)
e00004-17.
114. Newman JV, Zhou J, Izmailyan S, Tsai L. Randomized, 
double-blind, placebo-controlled studies of the safety and 
pharmacokinetics of single and multiple ascending doses 
of eravacycline. Antimicrob Agents Chemother. 2018 
Oct;62(11):e01174–01118. 
115. ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2000 Feb 29 - . Identifier 
NCT03450187, A phase 1 TP-271 oral PK multiple 
ascending dose study; 2018 Feb 16 [cited 2019 Sep 30]; 
[about 10 screens]. Available from: https://clinicaltrials.
gov/ct2/show/NCT03450187
116. ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2000 Feb 29 - . Identifier 
NCT03024034, A phase 1 TP-271 oral PK single ascending 
dose study; 2017 Jan 9 [cited 2019 Sep 30]; [about 8 
screens]. Available from: https://clinicaltrials.gov/ct2/
show/NCT03024034
117. Falagas ME, Skalidis T, Vardakas KZ, Voulgaris GL, 
Papanikolaou G, Legakis N; Hellenic TP-6076 Study 
Group. Activity of TP-6076 against carbapenem-resistant 
Acinetobacter baumannii isolates collected from 
inpatients in Greek hospitals. Int J Antimicrob Agents. 
2018 Aug;52(2):269–71. 
118. Grossman TH, Fyfe C, Kerstein K, Xiao X, Sun C, Newman 
J, Nguyen P, Pulse M, Weiss WJ, Dumas J, Sutcliffe JA. 
TP-6076 is efficacious in a mouse pneumonia model 
with carbapenem-resistant Acinetobacter baumannii 
(CRAB) and retains potency against common tetracycline-
resistance mechanisms. Poster presented at: 26th 
European Congress of Clinical Microbiology and Infectious 
Diseases (ECCMID); 2016 Apr 9-12; Amsterdam, 
Netherlands.
119. Seifert H, Stefanik D, Sutcliffe J, Higgins PG. In-vitro 
activity of the novel fluorocycline TP-6076 against 
14ULJRI Vol 3, (2) 2019
carbapenem non-susceptible Acinetobacter baumannii. 
Poster presented at: 27th European Congress of Clinical 
Microbiology and Infectious Diseases (ECCMID); 2017 Apr 
22-25; Vienna, Austria.
120. Fyfe C, Close B, LeBlanc G, Newman J. TP-6076 is 
active against carbapenem- and polymyxin-resistant 
Enterobacteriaceae and Acinetobacter baumannii isolates 
in the FDA-CDC antimicrobial isolate bank panels. 
Abstract presented at: 27th European Congress of Clinical 
Microbiology and Infectious Diseases (ECCMID); 2017 Apr 
22-25; Vienna, Austria.
121. Tsai L, Moore A. Safety, tolerability and pharmacokinetics 
of multiple doses of TP-6076, a novel, fully synthetic 
tetracycline, in a phase 1 study. In Open Forum Infect Dis. 
2018 Nov; 5(Suppl 1): S420.
122. ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2000 Feb 29 - . Identifier 
NCT03691584, Phase 1, safety and bronchopulmonary 
PK study in healthy volunteers (BAL); 2018 Sep 27 [cited 
2019 Sep 30]; [about 6 screens]. Available from: https://
clinicaltrials.gov/ct2/show/NCT03691584
123. Daigle D, Hamrick J, Chatwin C, Kurepina N, Kreiswirth 
BN, Shields RK, et al. 1370. Cefepime/VNRX-5133 broad-
spectrum activity is maintained against emerging KPC-and 
PDC-variants in multidrug-resistant K. pneumoniae and P. 
aeruginosa. In Open Forum Infect Dis. 2018 Nov(Suppl 1): 
S419-S420.
124. Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-
Wallace KM, et al. Potent β-lactam enhancer activity 
of zidebactam and WCK 5153 against Acinetobacter 
baumannii, including carbapenemase-producing 
clinical isolates. Antimicrob Agents Chemother. 2017 
Oct;61(11):e01238–01217. 
125. Sader HS, Castanheira M, Huband M, Jones RN, Flamm 
RK. WCK 5222 (cefepime-zidebactam) antimicrobial 
activity against clinical isolates of Gram-negative 
bacteria collected worldwide in 2015. Antimicrob Agents 
Chemother. 2017 Apr;61(5):e00072-17. 
126. Avery LM, Abdelraouf K, Nicolau DP. Assessment of the in 
vivo efficacy of WCK 5222 (cefepime-zidebactam) against 
carbapenem-resistant Acinetobacter baumannii in the 
neutropenic murine lung infection model. Antimicrob 
Agents Chemother. 2018 Oct;62(11):e00948–00918. 
127. Preston RA, Mamikonyan G, DeGraff S, Chiou J, 
Kemper CJ, Xu A, et al. Single-Center Evaluation of the 
Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam 
Combination) in Subjects with Renal Impairment. 
Antimicrob Agents CH. 2019 Jan 1;63(1):e01484-18.
128. Chugh R, Lakdavala F, Friedland HD, Bhatia A. Safety and 
pharmacokinetics of multiple ascending doses of WCK 5107 
(zidebactam) and WCK 5222 (cefepime and zidebactam). 
Poster presented at: 27th European Congress of Clinical 
Microbiology and Infectious Diseases (ECCMID); 2017 Apr 
22-25; Vienna, Austria.
129. Rodvold KA, Gotfried MH, Chugh R, Gupta M, Patel 
A, Chavan R, et al. Plasma and intrapulmonary 
concentrations of cefepime and zidebactam following 
intravenous administration of WCK 5222 to healthy 
adult subjects. Antimicrob Agents Chemother. 2018 
Jul;62(8):e00682–00618. 
130. AiCuris Pharmaceuticals. AiCuris initiates clinical 
development of AIC499, a novel resistance-breaking 
antibiotic against a broad range of MDR Gram-negative 
bacteria [press release] (2017 Jan 4) [cited 2019 Sep 30]. 
Available from: http://www.aicuris.com/74n93AiCuris-
Initiates-Clinical-Development-of-AIC499,-a-Novel-
Resistance-Breaking-Antibiotic-against-a-Broad-Range-
of-MDR-Gram-Negative-Bacteria.htm
131. Hackel M, Butler D, Miller LG, Bouchillon SK, Sahm DF. In 
vitro antibacterial activity of GSK3342830 against a global 
collection of clinically relevant Gram-negative bacteria. 
Am Soc Microbiol. 2017 Jun:1-5.
132. Tenero D, Farinola N, Berkowitz E, Tiffany CA, Qian Y, 
Xue Z, et al. Pharmacokinetics, safety, and tolerability 
evaluation of single and multiple doses of GSK3342830 
in healthy volunteers. Clin Pharmacol Drug Dev. 
2018;cpdd.637.; Epub ahead of print. 
133. Zurawski DV, Reinhart AA, Alamneh YA, Pucci MJ, Si 
Y, Abu-Taleb R, et al. SPR741, an antibiotic adjuvant, 
potentiates the in vitro and in vivo activity of rifampin 
against clinically relevant extensively drug-resistant 
Acinetobacter baumannii. Antimicrob Agents Chemother. 
2017 Nov;61(12):e01239–01217. 
134. Warn P, Teague J, Corbett D, Payne L, Burgess E, 
Lister T, Parr T.  In-vivo efficacy of combinations of 
novel antimicrobial peptide SPR741 and rifampicin in 
neutropenic murine pneumonia models of Gram-negative 
bacterial infections. Abstract presented at: 27th European 
Congress of Clinical Microbiology and Infectious Diseases 
(ECCMID); 2017 Apr 22-25; Vienna, Austria.
135. Utley L, Lister T, Coleman S, Eckburg P. Determination 
of the pharmacokinetics of single (SAD) and multiple 
ascending doses (MAD) of SPR741 in healthy volunteers. 
Abstract presented at: 28th European Congress of Clinical 
Microbiology and Infectious Diseases (ECCMID); 2018 
Apr 21-24; Madrid, Spain.
136. ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2000 Feb 29 - . Identifier 
NCT03376529, Phase 1 study to evaluate DDI, PK, safety, 
tolerability of SPR741; 2017 Dec 5 [cited 2019 Sep 30]; 
[about 9 screens]. Available from: https://clinicaltrials.
gov/ct2/show/NCT03376529
137. ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2000 Feb 29 - . Identifier 
NCT03022175, A first in human study of the safety and 
tolerability of single and multiple doses of SPR741 in 
healthy volunteers; 2016 Dec 16 [cited 2019 Sep 30]; 
[about 7 screens]. Available from: https://clinicaltrials.
gov/ct2/show/NCT03022175
138. Wang-Lin SX, Balthasar JP. Pharmacokinetic and 
pharmacodynamic considerations for the use of 
monoclonal antibodies in the treatment of bacterial 
infections. Antibodies (Basel). 2018 Jan;7(1):5. 
139. Motley MP, Fries BC. A new take on an old remedy: 
generating antibodies against multidrug-resistant Gram-
negative bacteria in a postantibiotic world. MSphere. 2017 
Oct;2(5):e00397–00317. 
140. McConnell MJ, Rumbo C, Bou G, Pachón J. Outer membrane 
vesicles as an acellular vaccine against Acinetobacter 
baumannii. Vaccine. 2011 Aug;29(34):5705–10. 
141. McConnell MJ, Pachón J. Active and passive immunization 
against Acinetobacter baumannii using an inactivated 
whole cell vaccine. Vaccine. 2010 Dec;29(1):1–5. 
142. Huang W, Yao Y, Long Q, Yang X, Sun W, Liu C, et al. 
Immunization against multidrug-resistant Acinetobacter 
baumannii effectively protects mice in both pneumonia 
and sepsis models. PLoS One. 2014 Jun;9(6):e100727. 
143. Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD, 
St Michael F, et al. The K1 capsular polysaccharide from 
Acinetobacter baumannii is a potential therapeutic 
15ULJRI Vol 3, (2) 2019
target via passive immunization. Infect Immun. 2013 
Mar;81(3):915–22. 
144. Nielsen TB, Pantapalangkoor P, Luna BM, Bruhn KW, 
Yan J, Dekitani K, et al. Monoclonal antibody protects 
against Acinetobacter baumannii infection by enhancing 
bacterial clearance and evading sepsis. J Infect Dis. 2017 
Aug;216(4):489–501. 
145. Nwokoro E, Leach R, Årdal C, Baraldi E, Ryan K, Plahte 
J. An assessment of the future impact of alternative 
technologies on antibiotics markets. J Pharm Policy Pract. 
2016 Oct;9(1):34. 
146. Doss J, Culbertson K, Hahn D, Camacho J, Barekzi N. 
A review of phage therapy against bacterial pathogens 
of aquatic and terrestrial organisms. Viruses. 2017 
Mar;9(3):50. 
147. El Haddad L, Harb CP, Gebara MA, Stibich MA, Chemaly 
RF. A systematic and critical review of bacteriophage 
therapy against multi-drug resistant ESKAPE organisms in 
humans. Clin Infect Dis. 2018.
148. Knezevic P, Curcin S, Aleksic V, Petrusic M, Vlaski L. 
Phage-antibiotic synergism: a possible approach to 
combatting Pseudomonas aeruginosa. Res Microbiol. 
2013 Jan;164(1):55–60. 
149. Cisek AA, Dąbrowska I, Gregorczyk KP, Wyżewski Z. Phage 
therapy in bacterial infections treatment: one hundred 
years after the discovery of bacteriophages. Curr Microbiol. 
2017 Feb;74(2):277–83. 
150. Cha K, Oh HK, Jang JY, Jo Y, Kim WK, Ha GU, et al. 
Characterization of two novel bacteriophages infecting 
multidrug- resistant (MDR) Acinetobacter baumannii 
and evaluation of their therapeutic efficacy in vivo. Front 
Microbiol. 2018 Apr;9:696. 
151. Jeon J, D’Souza R, Pinto N, Ryu CM, Park J, Yong D, et 
al. Characterization and complete genome sequence 
analysis of two Myoviral bacteriophages infecting clinical 
carbapenem-resistant Acinetobacter baumannii isolates. J 
Appl Microbiol. 2016 Jul;121(1):68–77. 
152. Jeon J, Ryu CM, Lee JY, Park JH, Yong D, Lee K. In vivo 
application of bacteriophage as a potential therapeutic 
agent to control OXA-66-like carbapenemase-producing 
Acinetobacter baumannii strains belonging to sequence 
type 357. Appl Environ Microbiol. 2016 Jun;82(14):4200-
8. 
153. Kusradze I, Karumidze N, Rigvava S, Dvalidze T, Katsitadze 
M, Amiranashvili I, et al. Characterization and testing the 
efficiency of Acinetobacter baumannii phage vB-GEC_Ab-
M-G7 as an antibacterial agent. Front Microbiol. 2016 
Oct;7:1590. 
154. Shivaswamy VC, Kalasuramath SB, Sadanand CK, 
Basavaraju AK, Ginnavaram V, Bille S, et al. Ability 
of bacteriophage in resolving wound infection caused 
by multidrug-resistant Acinetobacter baumannii in 
uncontrolled diabetic rats. Microb Drug Resist. 2015 
Apr;21(2):171–7. 
155. Hua Y, Luo T, Yang Y, et al. Phage therapy as a promising 
new treatment for lung infection caused by carbapenem-
resistant Acinetobacter baumannii in mice. Front 
Microbiol. 2018;8:2659.
156. LaVergne S, Hamilton T, Biswas B, Kumaraswamy M, 
Schooley RT, Wooten D. Phage therapy for a multidrug-
resistant Acinetobacter baumannii craniectomy site 
infection. Open Forum Infect Dis. 2018 Mar;5(4):ofy064. 
157. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, 
Lancaster J, Lessor L, et al. Development and use of 
personalized bacteriophage-based therapeutic cocktails to 
treat a patient with a disseminated resistant Acinetobacter 
baumannii infection. Antimicrob Agents Chemother. 2017 
Sep;61(10):e00954-17. 
158. Bassetti M, Corey R, Doi Y, Morrissey I, Grossman T, 
Olesky M, Sutcliffe J. In Vitro Global Surveillance of 
Eravacycline and Comparators Against Enterobacteriace-
ae, Acinetobacter baumannii, Stenotrophomonas malto-
philia, Including Multidrug-resistant (MDR) Isolates, Over 
a Three-year Period (2013-15). Poster presented at: ID-
Week 2016; 2016 Oct 26-30; New Orleans, LA.
159. Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH. Antibacterial 
activity of eravacycline (TP-434), a novel fluorocycline, 
against hospital and community pathogens. Antimicrob 
Agents Chemother. 2013 Nov;57(11):5548–58. 
160. Tsuji M, Hackel M, Echols R, Yamano Y, Sahm DF. In 
vitro activity of cefiderocol against globally collected 
carbapenem-resistant Gram-negative bacteria isolated 
from urinary tract source: SIDERO-CR-2014/2016.  In 
Open Forum Infect Dis. 2018 Nov(Suppl 1): S366.
